Cipla teams up with Roche to sell 2 cancer drugs in India

February 28, 2018 | Wednesday | News

The pharma major will distribute Tocilizumab and Syndyma, the second brand of Roche's cancer therapy bevacizumab in India.

Image credit- sciencedaily.com

Image credit- sciencedaily.com

Mumbai based drug firm Cipla has entered into an agreement with Roche Pharma to promote and distribute the latter's cancer drugs in India.

The pharma major will distribute Tocilizumab and Syndyma, the second brand of Roche's cancer therapy bevacizumab in India.

This partnership is in line with Cipla and Roche's efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

Accroding to cipla, the prevalence of cancer and rheumatoid arthritis is widely spread across India, and the company intends to contribute to provide broader access to innovative medicines like tocilizumab and bevacizumab.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy